Recordati Rare Diseases Inc. announced today that various scientific abstracts have been accepted and will be presented onsite at the ENDO 2022 annual meeting being held in Atlanta, Georgia from June
Moscow, Russia: New research found that oral octreotide was not inferior to injectable somatostatin receptor ligands (iSRLs) medication and may be a better option for many people with acromegaly. This.
Many patients with acromegaly may do as well on oral octreotide treatment as they do on injectable somatostatin receptor ligands, an industry-sponsored phase 3 trial suggests.